dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Macarulla Mercadé, Teresa |
dc.contributor.author | Blanc, Jean-Frédéric |
dc.contributor.author | Wang-Gillam, Andrea |
dc.contributor.author | Chen, Li-Tzong |
dc.contributor.author | Siveke, Jens T. |
dc.contributor.author | Mirakhur, Beloo |
dc.date.accessioned | 2021-03-19T12:33:13Z |
dc.date.available | 2021-03-19T12:33:13Z |
dc.date.issued | 2019-05-01 |
dc.identifier.citation | Macarulla T, Blanc JF, Wang-Gillam A, Chen LT, Siveke JT, Mirakhur B, et al. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer – A subgroup analysis of the pivotal NAPOLI-1 trial. J Geriatr Oncol. 2019 May 1;10(3):427–35. |
dc.identifier.issn | 1879-4068 |
dc.identifier.uri | https://hdl.handle.net/11351/5777 |
dc.description | Irinotecán liposomal; Pacientes mayores; Cáncer de páncreas |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Journal of Geriatric Oncology;10 |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Pàncrees - Càncer |
dc.subject | Metàstasi |
dc.subject | Medicaments - Administració |
dc.subject.mesh | Pancreatic Neoplasms |
dc.subject.mesh | Fluorouracil |
dc.subject.mesh | /administration & dosage |
dc.subject.mesh | Neoplasm Metastasis |
dc.title | Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.jgo.2019.02.011 |
dc.subject.decs | neoplasias pancreáticas |
dc.subject.decs | fluorouracilo |
dc.subject.decs | /administración & dosificación |
dc.subject.decs | metástasis neoplásica |
dc.relation.publishversion | https://linkinghub.elsevier.com/retrieve/pii/S1879-4068(18)30349-7 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Macarulla T] Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Blanc JF] Pôle ADEN, Hôpital Haut-Lévêque, CHU Bordeaux, Bordeaux, France. [Wang-Gillam A] Division of Oncology, Washington University in St. Louis, MO, USA. [Chen LT] National Institute of Cancer Research, National Health Research Institutes, National Cheng Kung University, Tainan, Taiwan. Department of Internal Medicine, National Cheng Kung University, Tainan, Taiwan. [Siveke JT] Division of Solid Tumor Translational Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany. Cancer Consortium (DKTK, partner site Essen), German Cancer Research Center, DKFZ, Heidelberg, Germany. [Mirakhur B] Ipsen Biopharmaceuticals, Inc., Cambridge, MA, United States |
dc.identifier.pmid | 30842038 |
dc.identifier.wos | 000470049200012 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |